NASDAQ
FWBI

First Wave BioPharma Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

First Wave BioPharma Inc Stock Price

Vitals

Today's Low:
$0.3775
Today's High:
$0.4199
Open Price:
$0.4061
52W Low:
$0.273
52W High:
$20.6506
Prev. Close:
$0.403
Volume:
331813

Company Statistics

Market Cap.:
$2.07 million
Book Value:
0.21
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-92.89%
Return on Equity TTM:
-2343.29%

Company Profile

First Wave BioPharma Inc had its IPO on 2016-10-11 under the ticker symbol FWBI.

The company operates in the Healthcare sector and Biotechnology industry. First Wave BioPharma Inc has a staff strength of 10 employees.

Stock update

Shares of First Wave BioPharma Inc opened at $0.41 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.38 - $0.42, and closed at $0.4.

This is a -0.6% slip from the previous day's closing price.

A total volume of 331,813 shares were traded at the close of the day’s session.

In the last one week, shares of First Wave BioPharma Inc have increased by +38.14%.

First Wave BioPharma Inc's Key Ratios

First Wave BioPharma Inc has a market cap of $2.07 million, indicating a price to book ratio of 2.8181 and a price to sales ratio of 0.

In the last 12-months First Wave BioPharma Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-6104937. The EBITDA ratio measures First Wave BioPharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, First Wave BioPharma Inc’s operating margin was 0% while its return on assets stood at -92.89% with a return of equity of -2343.29%.

In Q2, First Wave BioPharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

First Wave BioPharma Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0.0022
PEG

Its diluted EPS in the last 12-months stands at $134.86 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into First Wave BioPharma Inc’s profitability.

First Wave BioPharma Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.1113. Its price to sales ratio in the trailing 12-months stood at 0.

First Wave BioPharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$4.33 million
Total Liabilities
$3.26 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

First Wave BioPharma Inc ended 2024 with $4.33 million in total assets and $0 in total liabilities. Its intangible assets were valued at $4.33 million while shareholder equity stood at $881960.00.

First Wave BioPharma Inc ended 2024 with $0 in deferred long-term liabilities, $3.26 million in other current liabilities, 421.00 in common stock, $-176793574.00 in retained earnings and $1.68 million in goodwill. Its cash balance stood at $1.24 million and cash and short-term investments were $1.24 million. The company’s total short-term debt was $217,042 while long-term debt stood at $0.

First Wave BioPharma Inc’s total current assets stands at $2.35 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.59 million and inventory worth $0.

In 2024, First Wave BioPharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, First Wave BioPharma Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.4
52-Week High
$20.6506
52-Week Low
$0.273
Analyst Target Price
$126

First Wave BioPharma Inc stock is currently trading at $0.4 per share. It touched a 52-week high of $20.6506 and a 52-week low of $20.6506. Analysts tracking the stock have a 12-month average target price of $126.

Its 50-day moving average was $0.62 and 200-day moving average was $2.78 The short ratio stood at 0.12 indicating a short percent outstanding of 0%.

Around 77.4% of the company’s stock are held by insiders while 165.4% are held by institutions.

Frequently Asked Questions About First Wave BioPharma Inc

The stock symbol (also called stock or share ticker) of First Wave BioPharma Inc is FWBI

The IPO of First Wave BioPharma Inc took place on 2016-10-11

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$1.3
0.02
+1.56%
$79.19
0.94
+1.2%
$29.24
0.42
+1.46%
$79.36
-0.57
-0.71%
$47.83
-5.12
-9.67%
Splunk Inc (SPLK)
$122.6
-1.54
-1.24%
$10.14
0
-4.54%
$23.59
-0.21
-0.88%
$0.71
0
+0.58%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn’s disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Address

777 Yamato Road, Boca Raton, FL, United States, 33431